CryoLife

CryoLife, headquartered in Georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. CryoLife using its proprietary SynerGraft® technology processes the CryoValve® SG pulmonary heart valve and CryoPatch® SG pulmonary cardiac patch. CryoLife’s BioGlue® Surgical Adhesive is approved in the U.S. for use as an adjunct to sutures and staples to help control bleeding, CE marked in the European Community, approved in Canada and Australia for use in soft tissue repair, and in Japan for use in the repair of aortic dissections. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO® Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot®, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.
Company Growth (employees)
Type
Public
HQ
Kennesaw, US
Founded
1984
Size (employees)
665 (est)+24%
CryoLife was founded in 1984 and is headquartered in Kennesaw, US

Key People at CryoLife

Steven G. Anderson

Steven G. Anderson

Chairman, President and CEO
Thomas F. Ackerman

Thomas F. Ackerman

Thomas F. Ackerman Executive Vice President and CFO

CryoLife Office Locations

CryoLife has offices in Kennesaw, Guildford, Singapore
Kennesaw, US (HQ)
1655 Roberts Blvd
Singapore, SG
Marina Blvd
Guildford, GB
Old Portsmouth Rd

CryoLife Metrics

CryoLife Financial Metrics

Revenue (2016)

$180.4 m

Revenue growth (2015-16), %

24%

Net income (2016)

$10.8 m

Market capitalization (21-Mar-2017)

$557.4 m

Closing share price (21-Mar-2017)

$17

Cash (31-Dec-2016)

$56.6 m
CryoLife's current market capitalization is $557.4 m.
CryoLife's revenue was reported to be $180.4 m in FY, 2016 which is a 23.6% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$140.8 m$144.6 m$145.9 m$180.4 m

Revenue growth, %

3%1%24%

Gross profit

$90.4 m$91.3 m$90.7 m

Gross profit Margin, %

64%63%62%

Operating expense total

$76.6 m$82.5 m$85.4 m$105 m

EBIT

$13.8 m$8.8 m$5.4 m$21.8 m

EBIT margin, %

10%6%4%12%

Interest expense

$175 k$62 k$3 m

Interest income

$50 k$45 k$72 k

Pre tax profit

$8.7 m$5.9 m$18.4 m

Income tax expense

$1.4 m$1.9 m$7.6 m

Net Income

$16.2 m$7.3 m$4 m$10.8 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$37.6 m$33.4 m$37.6 m$56.6 m

Accounts Receivable

Inventories

$9.8 m$12.7 m$14.6 m$26.3 m

Current Assets

$106.3 m$106 m$109.7 m$147.2 m

Goodwill

$11.4 m$11.4 m$11.4 m$78.3 m

Total Assets

$174.7 m$176.2 m$181.2 m$316.1 m

Accounts Payable

$4.1 m$4.5 m$4.6 m$5.7 m

Total Debt

$71.6 m

Current Liabilities

$20.7 m$20.6 m$19.6 m$30.1 m

Preferred Stock

Additional Paid-in Capital

$128.6 m$135.2 m$142.9 m$187.1 m

Retained Earnings

$18.7 m$22.8 m$23.4 m$34.1 m

Total Equity

$144.7 m$148.7 m$155.3 m$209 m

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.2 x1.2 x1.2 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$16.2 m$7.3 m$4 b$10.8 m

Depreciation and Amortization

$5.8 m$6 m$5.9 b$8.4 m

Accounts Receivable

Inventories

Accounts Payable

Cash From Operating Activities

$24.6 m($4.3 m)$4.2 m

Capital Expenditures

($4.3 m)($4.3 m)($3.5 b)($6.2 m)

Cash From Investing Activities

($73.9 m)

Dividends Paid

($3 m)($3.3 m)($3.4 b)($3.4 m)

Cash From Financing Activities

($3.1 m)($7 m)($2.8 b)

CryoLife Market Value History

CryoLife Online Presence

CryoLife Company Life

You may also be interested in